• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Korro Bio Inc.

    4/29/25 6:06:51 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KRRO alert in real time by email
    DEFA14A 1 korro_defa14a_2025.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the Securities

    Exchange Act of 1934 (Amendment No. )

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

     

    Check the appropriate box:

     

     

    ☐

    Preliminary Proxy Statement

     

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

     

    ☐

    Definitive Proxy Statement

     

     

    ☒

    Definitive Additional Materials

     

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

     

     

    Korro Bio, Inc.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

     

    Payment of Filing Fee (Check all boxes that apply):

     

     

    ☒

    No fee required

     

     

    ☐

    Fee paid previously with preliminary materials

     

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

     

     

     

     

     

     


     

    img161143922_0.jpg

     

    korro bio P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! Korro Bio, Inc. Annual Meeting of Stockholders Wednesday, June 11, 2025 11:00 AM, Eastern Time Annual meeting to be held via the Internet - please visit www.proxydocs.com/KRRO for more details. You must register to attend the meeting online and/or participate by 5:00 PM ET on June 10, 2025 at www.proxydocs.com/KRRO. For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/KRRO To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 30, 2025. SEE REVERSE FOR FULL AGENDA Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting to be Held on June 11, 2025 for Stockholders of Record as of April 15, 2025 To order paper materials, use one of the following methods. Internet: www.investorelections.com/KRRO Call: 1-866-648-8133 Email: [email protected] * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions.

     


     

    img161143922_1.jpg

     

    korro bio Korro Bio, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR THE NOMINEES IN PROPOSAL 1, FOR A FREQUENCY OF ONE YEAR IN PROPOSAL 3 AND FOR PROPOSALS 2 AND 4 PROPOSAL 1. Election of three Class III directors nominated by our board of directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders; 1.01 Ram Aiyar 1.02 Jean-Francois Formela 1.03 Katharine Knobil 2. Non-Binding Advisory Vote to Approve the Compensation of our Named Executive Officers; 3. Non-Binding Advisory Vote on the Frequency of Future Non-Binding Advisory Votes to Approve the Compensation of our Named Executive Officers 4. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; 5. Transaction of any other business that may properly come before the Annual Meeting or any adjournment or postponement thereof.

     


     

     


    Get the next $KRRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KRRO

    DatePrice TargetRatingAnalyst
    4/29/2025$74.00Overweight
    Cantor Fitzgerald
    4/16/2025$25.00Buy
    Chardan Capital Markets
    1/10/2025$155.00Outperform
    Oppenheimer
    10/21/2024$153.00Strong Buy
    Raymond James
    8/14/2024$180.00Outperform
    William Blair
    3/28/2024$100.00 → $115.00Buy
    H.C. Wainwright
    2/27/2024$120.00Outperform
    BMO Capital Markets
    12/4/2023$100.00Buy
    H.C. Wainwright
    More analyst ratings

    $KRRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Korro Bio with a new price target

      Cantor Fitzgerald initiated coverage of Korro Bio with a rating of Overweight and set a new price target of $74.00

      4/29/25 8:10:45 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital Markets initiated coverage on Korro Bio with a new price target

      Chardan Capital Markets initiated coverage of Korro Bio with a rating of Buy and set a new price target of $25.00

      4/16/25 9:07:30 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Korro Bio with a new price target

      Oppenheimer initiated coverage of Korro Bio with a rating of Outperform and set a new price target of $155.00

      1/10/25 8:59:40 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mathers Edward T bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      4/24/24 5:00:19 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Florence Anthony A. Jr. bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      4/24/24 5:00:26 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Yang Rick bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      4/24/24 5:00:16 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Scientific Officer Vincent Loic A

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      4/1/25 9:46:16 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Senior Vice President, Finance Dolan Oliver

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      4/1/25 9:46:19 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Vincent Loic A

      3 - Korro Bio, Inc. (0001703647) (Issuer)

      4/1/25 9:43:14 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Korro Bio Inc.

      10-Q - Korro Bio, Inc. (0001703647) (Filer)

      5/7/25 4:40:22 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

      8-K - Korro Bio, Inc. (0001703647) (Filer)

      5/7/25 4:35:10 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Korro Bio Inc.

      DEFA14A - Korro Bio, Inc. (0001703647) (Filer)

      4/29/25 6:06:51 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Korro to Participate in Upcoming Investor Conferences

      CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) today announced that members of management will participate in the following upcoming investor conferences: 2025 RBC Capital Markets Global Healthcare ConferenceRam Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Wednesday, May 21, 2025, at 2:35 p.m. ET. Jefferies Global Healthcare Conference Dr. Aiyar and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will present on Wednesday, June 4, 2025, at 9:55 a.m. ET. Goldman Sachs 46th Annual Global Healthcare Conference Dr. Aiyar and Dr. Olugemo, will present on Monday, June 9, 2025, at 4:00 p.m. ET. A live webc

      5/14/25 4:05:00 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

      —Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) on track for the second half of 2025  —Streamlining operations and focusing on delivering potential value generating program milestones, with workforce reduction of approximately 20% and cost reductions expected to extend cash runway into 2027   —Second development candidate expected to be announced in 2025  —Ended first quarter 2025 with $139.0 million in cash, cash equivalents and marketable securities     CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of gene

      5/7/25 4:30:00 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

      CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company's Chief Scientific Officer. "We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy," said Ram Aiyar, Ph.D., CEO and President of Korro. "He joins us at an important time as we advance multiple candidates i

      4/1/25 7:30:00 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

      SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

      11/14/24 7:54:42 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

      SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

      11/14/24 3:04:22 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

      SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

      11/14/24 12:21:08 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

      CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company's Chief Scientific Officer. "We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy," said Ram Aiyar, Ph.D., CEO and President of Korro. "He joins us at an important time as we advance multiple candidates i

      4/1/25 7:30:00 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

      CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

      12/10/24 8:00:00 AM ET
      $CAMP
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

      - Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team - Partnered with Novo Nordisk to develop up to two targets for cardiometabolic diseases leveraging Korro's proprietary OPERATM platform - Ended third quarter of 2024 with $169.1 million in cash, cash equivalents and marketable securities - Cash runway into the second half of 2026 expected to fund KRRO-110 through completion of a Phase 1/2 clinical study and progress additional pipeline candidates CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ko

      11/12/24 4:05:00 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care